Pluristem Life Systems, Inc. (OTCBB:PLRS) (DAX:PJT), a leading bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, Ischemic and auto-immune disorders, announced today that it has completed the construction of its new state-of-the-art GMP (Good Manufacturing Practice) facilities which are designed to support the manufacturing process of the Company’s PLX-I (PLacenta eXpanded) cells for the upcoming Phase I clinical trials, in which PLX-I will be used with cord blood as an alternative to bone marrow transplantation. Additionally, these facilities will be sufficient to enable large-scale commercial production of PLX cells.
